Clinical Research Directory
Browse clinical research sites, groups, and studies.
Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)
Sponsor: Central Hospital, Nancy, France
Summary
Assess the impact of eplerenone (initiated within 2 hours prior to patient departure to the operating room and administered for 4 days during the post-operative period) on graft function evaluated by the measurement of glomerular filtration rate at 3 months - variable strongly associated with long-term graft survival.
Official title: Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
132
Start Date
2016-10-19
Completion Date
2031-08
Last Updated
2023-06-18
Healthy Volunteers
No
Conditions
Interventions
Eplerenone
Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
Placebo
Double-blinded Placebo administered for 4 days at 25mg every 12 hours
Locations (7)
CHRU Besançon
Besançon, France
CHU Brest
Brest, France
CHU Dijon- Hôpital Bocage Central
Dijon, France
CHRU de Nancy
Nancy, France
CHU Reims-Hôpital Maison Blanche
Reims, France
CHU Saint Etienne
Saint-Etienne, France
NHC -CHRU Strasbourg
Strasbourg, France